Table of Contents
Executive Summary — 7
SWOT
Analysis — 8
Israel Pharmaceuticals And Healthcare
Industry SWOT — 8
Israel Political
SWOT — 9
Israel Economic SWOT — 10
Israel Business Environment SWOT — 10
Pharmaceutical
Business Environment Ratings — 11
Table: Middle East and
Africa - Regional Pharmaceuticals Business Environment Ratings For
Q309 — 11
Limits To Potential
Returns — 12
Risks To Realisation Of
Returns — 12
Israel – Market
Summary — 14
Regulatory Regime — 15
Intellectual Property — 15
Recent IP
Developments — 17
Shortcomings Of The IP
Environment — 17
Counterfeit
Drugs — 20
Table: Top 10 Countries By Counterfeit
Pharmaceutical Seizures, 2006 — 20
Pricing
System — 21
Price Cuts — 22
Reimbursement System — 23
Recent Reimbursement
Developments — 24
Funding For
Reimbursement — 25
Industry
Trends — 26
Epidemiology — 26
Healthcare Sector — 26
Healthcare
Insurance — 27
Recent Healthcare Coverage
Developments — 28
Healthcare
Financing — 29
Pharmaceutical
Industry — 30
Recent Pharmaceutical Industry
Developments — 31
Retail Pharmacy
Sector — 34
Research And Development
Sector — 34
Table: Israel’s R&D Law –
Conditions For OCS Funding — 36
Biotechnology — 36
Recent Biotechnology
Developments — 37
International Research And Development
Co-operation — 38
Private Sector — 39
Medical Device Industry — 39
Recent Medical Device Company
Developments — 40
Industry Forecast
Scenario — 42
Overall Market
Forecast — 42
Table: Israel – Drug Market
Indicators, Historical Data and Forecasts — 43
Key Growth
Factors – Industry — 44
Table: Israel – Health
Expenditure Indicators, Historical Data and Forecasts — 45
Key Growth Factors – Macroeconomic — 45
Table:
Israel – Economic Activity, 2006-2013 — 48
Prescription Market Forecast — 48
Table: Israel –
Prescription Market Indicators, Historical Data and Forecasts (ILSmn unless
otherwise stated) — 49
Patented Market
Forecast — 51
Patented Market
Forecast — 51
Table: Israel – Patented Drug Market
Indicators, Historical Data and Forecasts — 51
Generic
Drug Market Forecast — 52
Table: Israel - Generics Market
Indicators, Historical Data and Forecasts — 52
OTC Market
Forecast — 53
Table: Israel – OTC Market Indicators,
Historical Data and Forecasts (ILSmn unless otherwise
stated) — 54
Medical Device Market
Forecast — 55
Table: Israel – Medical Device Market
Indicators, Historical Data and Forecasts — 56
Pharmaceutical Trade Forecast — 57
Table: Israel –
Pharmaceutical Trade Indicators, Historical Data and Forecast
(US$mn) — 58
Other Healthcare Data
Forecasts — 59
Table: Israel – Other Healthcare
Indicators, Historical Data and Forecasts — 60
Key Risks
To BMI’s Forecast Scenario — 60
Competitive
Landscape — 61
Company Profiles — 62
Multinationals — 62
Pfizer — 62
Novartis — 63
Sanofi-Aventis — 64
GlaxoSmithKline — 65
Merck & Co — 66
Indigenous Manufacturer Profiles — 67
Teva Pharmaceutical
Industries — 67
Taro — 75
Perrigo
(Agis Industries) — 78
Dexcel — 80
Trima — 82
Rekah — 83
Country
Snapshot: Israel Demographic Data — 85
Section 1:
Population — 85
Table: Demographic Indicators,
2005-2030 — 85
Table: Rural/Urban Breakdown,
2005-2030 — 86
Section 2: Education And
Healthcare — 86
Table: Education,
2002-2005 — 86
Table: Vital Statistics,
2005-2030 — 86
Section 3: Labour Market And Spending
Power — 87
Table: Employment Indicators,
2001-2006 — 87
Table: Consumer Expenditure, 2000-2012
(US$) — 87
Table: Average Annual Wages,
2000-2012 — 88
BMI Forecast
Modelling — 89
How We Generate Our Pharmaceutical Industry
Forecasts — 89
Pharmaceutical Business Environment Ratings
Methodology — 90
Ratings Overview — 90
Table: Pharmaceutical Business Environment Indicators — 91
Weighting — 92
Table: Weighting Of
Components — 92
Sources — 92
| 
View Cart
